

**PCT**WORLD INTELLECTUAL PROPERTY ORGANIZATION  
International Bureau

## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

<b>(51) International Patent Classification <sup>6</sup> :</b> <b>C07D 401/12, A61K 31/44</b>	<b>A1</b>	<b>(11) International Publication Number:</b> <b>WO 99/00380</b> <b>(43) International Publication Date:</b> 7 January 1999 (07.01.99)
<b>(21) International Application Number:</b> PCT/SE98/01124 <b>(22) International Filing Date:</b> 11 June 1998 (11.06.98) <b>(30) Priority Data:</b> 9702483-0      27 June 1997 (27.06.97)      SE <b>(71) Applicant (for all designated States except US):</b> ASTRA AKTIEBOLAG [SE/SE]; S-151 85 Södertälje (SE). <b>(72) Inventors; and</b> <b>(75) Inventors/Applicants (for US only):</b> GUSTAVSSON, Anders [SE/SE]; (SE). KJELLBOM, Kristina [SE/SE]; (SE). YMÉN, Ingvar [SE/SE]; Astra Production Chemicals AB, S-151 85 Södertälje (SE). <b>(74) Agent:</b> ASTRA AKTIEBOLAG; Patent Dept., S-151 85 Södertälje (SE).		<b>(81) Designated States:</b> AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, GW, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG).  <b>Published</b> <i>With international search report.</i>
<b>(54) Title:</b> OMEPRAZOLE SODIUM SALT  <b>(57) Abstract</b>  This invention relates to a novel form of the sodium salt of 5-methoxy-2-[[[4-methoxy-3,5-dimethyl-2-pyridinyl)methyl]sulfinyl]-1H-benzimidazole, known under the generic name of omeprazole sodium salt. This invention also relates to processes for its preparation of omeprazole sodium form B which is thermodynamically stable, as well as pharmaceutical compositions containing it and its use in the treatment of gastrointestinal disorders.		

**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Larvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece			TR	Turkey
BG	Bulgaria	HU	Hungary	ML	Mali	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MN	Mongolia	UA	Ukraine
BR	Brazil	IL	Israel	MR	Mauritania	UG	Uganda
BY	Belarus	IS	Iceland	MW	Malawi	US	United States of America
CA	Canada	IT	Italy	MX	Mexico	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NE	Niger	VN	Viet Nam
CG	Congo	KE	Kenya	NI	Netherlands	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NO	Norway	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	NZ	New Zealand		
CM	Cameroon	KR	Republic of Korea	PL	Poland		
CN	China			PT	Portugal		
CU	Cuba	KZ	Kazakhstan	RO	Romania		
CZ	Czech Republic	LC	Saint Lucia	RU	Russian Federation		
DE	Germany	LI	Liechtenstein	SD	Sudan		
DK	Denmark	LK	Sri Lanka	SE	Sweden		
EE	Estonia	LR	Liberia	SG	Singapore		

## OMEPRAZOLE SODIUM SALT

Field of the invention

5 This invention relates to a novel form of 5-methoxy-2-[[[(4-methoxy-3,5-dimethyl-2-pyridinyl)methyl]sulfinyl]-1H-benzimidazole, known under the generic name omeprazole. More specifically, it relates to a novel form of the sodium salt of omeprazole, namely a well-defined omeprazole sodium monohydrate salt, hereinafter referred to as omeprazole sodium form B, and its use in the treatment of gastrointestinal disorders, pharmaceutical  
10 compositions containing it and preparation thereof.

Background of the invention and prior art

The compound 5-methoxy-2-[[[(4-methoxy-3,5-dimethyl-2-pyridinyl)methyl]sulfinyl]-1H-  
15 benzimidazole having the generic name omeprazole, as well as therapeutically acceptable salts thereof, are described in EP 5129. The specific alkaline salts of omeprazole, such as the sodium salt, are disclosed in EP 124 495. The omeprazole sodium salt produced according to examples 1 and 2 of EP 124 495 is a mixture of crystal forms and amorphous material. One of the crystal forms present in this mixture, hereinafter referred to as  
20 omeprazole sodium form A, is a hydrate with one to two water molecules, of which one water molecule is strongly bound in the crystal structure while the other is easily removed by drying. The resulting dried substance containing one strongly bound water molecule is very hygroscopic and absorbs water rapidly under normal conditions.

25 Omeprazole is a proton pump inhibitor, *i.e.* effective in inhibiting gastric acid secretion, and is useful as an antiulcer agent. In a more general sense, omeprazole may be used for treatment of gastric-acid related diseases in mammals and especially in man.

### Brief description of the drawings

Figure 1 is an X-ray powder diffractogram of omeprazole sodium form B.

Figure 2 is an X-ray powder diffractogram of omeprazole sodium form A.

- 5 Figure 3 is an X-ray powder diffractogram of omeprazole sodium prepared according to prior art.

### Description of the invention

- 10 It has surprisingly been found that the sodium salt of omeprazole exists in a number of different crystal forms. It is an object of the present invention to provide a well-defined, thermodynamically stable at ambient temperature, and industrially useful form of omeprazole sodium, namely omeprazole sodium form B. Another object of the present invention is to provide a process for the preparation of omeprazole sodium form B,
- 15 substantially free from other forms of the sodium salt of omeprazole. X-ray powder diffraction (XRPD) is used as a method of differentiating omeprazole sodium form B from other forms of the sodium salt of omeprazole.

- It has been found that the sodium salt of omeprazole may crystallize in at least two
- 20 different crystal forms, of which omeprazole sodium form B is one. One other form is omeprazole sodium form A with one to two moles of water. Omeprazole sodium form A is one of the crystal forms present in the mixture of crystal forms and amorphous material obtained in example 1 and example 2 in EP 124 495. However, there is no omeprazole sodium form B present in the mixture of forms obtained when preparing omeprazole
- 25 sodium salt as described in either example 1 or example 2 in EP 124 495.

- Omeprazole sodium form B is a crystalline form exhibiting advantageous properties, such as being well-defined, stable, and being a true monohydrate crystal form. Omeprazole sodium form B is thermodynamically more stable than omeprazole sodium form A.
- 30 Omeprazole sodium form B is essentially non-hygrosopic and can therefore in industrial

processes, such as pharmaceutical manufacturing processes, be charged in a fixed amount in contrast to omeprazole sodium form A which must be charged in amounts calculated from a recent assay of omeprazole or indirectly from a recent assay of its water content. Other advantages include easier preparation and higher reproducibility between batches.

5 This is especially important in production scale and leads to a higher production capacity.

Omeprazole sodium form A, which is thermodynamically unstable, can under certain storing conditions be completely or partly converted to omeprazole sodium form B. Omeprazole sodium form B is thereby characterized in being thermodynamically more

10 stable than omeprazole sodium form A and any other form of omeprazole sodium prepared according to prior art. Omeprazole sodium form B is further characterized as being essentially non-hygroscopic.

With the expression "any other form" is meant anhydrides, hydrates, solvates and

15 amorphous materials, including polymorphs disclosed in the prior art. Examples of any other forms of sodium salts of omeprazole includes, but are not limited to, anhydrides, monohydrates, dihydrates, sesquihydrates, trihydrates, alcoholates and polymorphs or amorphous forms thereof.

20 Omeprazole sodium form B is characterized by the positions and intensities of the peaks in the X-ray powder diffractogram, as well as by the unit cell parameters which have been calculated from the peak positions. The corresponding data for omeprazole sodium form A are totally different, whereas form B is easily distinguishable from form A.

Omeprazole sodium form B according to the present invention is characterized in providing an X-ray powder diffraction pattern exhibiting substantially the following d-values;

d-value/Å	relative intensity	d-value/Å	relative intensity
9.8	vs	3.37	w
7.8	vw	3.25	vw
6.7	s	3.17	vw
6.5	s	3.14	w
6.2	vw	3.12	m
5.9	m	3.05	w
5.8	vw	2.99	w
5.4	w	2.98	m
5.1	w	2.91	m
4.6	m	2.89	m
4.5	m	2.79	vw
4.3	s	2.62	vw
4.1	m	2.59	vw
3.96	m	2.50	vw
3.92	m	2.45	vw
3.71	s	2.40	vw
3.60	w	2.37	vw
3.43	vw	2.28	vw

5

Omeprazole sodium form B according to the present invention is characterized by having a monoclinic unit cell with parameters

$$a = 15.09 \text{ Å}, b = 12.83 \text{ Å}, c = 9.82 \text{ Å}, \beta = 94.4^\circ.$$

According to the invention there is further provided a process for the preparation of omeprazole sodium form B as well as a process for the preparation of omeprazole sodium form A.

- 5 Omeprazole sodium form B can also be characterized by FT-IR.

Omeprazole sodium form B is prepared by treating omeprazole with an aqueous base,  $\text{Na}^+ \text{B}^-$ , wherein Na denotes sodium and B denotes hydroxide or alkoxide, in an appropriate solvent, such as isopropanol optionally containing some water, at ambient temperature.

- 10 Once the mixing has taken place the total mixture may be agitated, for example stirred, for a further period of time, *e.g.* about 0-2 hours, at ambient temperature. The crude mixture may optionally be filtered at this stage. Seeds of omeprazole sodium form B may be added to the crystallization solution in order to induce the crystallization. The slurry is thereafter further agitated for a time period of about 10-24 h to ensure as complete crystallization as possible. It is also possible to cool the mixture in order to complete the crystallization and thereby improving the yield. The omeprazole sodium form B is thereafter separated, for example by filtration or centrifugation, followed by washing with an appropriate solvent, preferably the same solvent as used above, and thereafter dried to constant weight.

- 20 Omeprazole sodium form B may also be prepared by recrystallizing the sodium salt of omeprazole of any form, or mixtures thereof, in an appropriate solvent such as ethanol or isopropanol, optionally containing some water.

- 25 The omeprazole sodium form B obtained according to the present invention is substantially free from other forms of sodium salts of omeprazole, such as omeprazole sodium form A.

The compound of the invention, *i.e.* omeprazole sodium form B, prepared according to the present invention is analyzed, characterized and differentiated from omeprazole sodium form A by X-ray powder diffraction, a technique which is known per se. Another suitable

technique to analyze, characterize and differentiate omeprazole sodium form B from omeprazole sodium form A is by conventional FT-IR.

The amount of water in omeprazole sodium form B and omeprazole sodium form A is  
5 determined by thermogravimetric analysis, a technique which is known per se. The water content can also be determined by Karl Fischer.

Omeprazole sodium form B is effective as a gastric acid secretion inhibitor, and is useful as an antiulcer agent. In a more general sense, it can be used for treatment of gastric-acid  
10 related conditions in mammals and especially in man, including *e.g.* reflux esophagitis, gastritis, duodenitis, gastric ulcer and duodenal ulcer. Furthermore, it may be used for treatment of other gastrointestinal disorders where gastric acid inhibitory effect is desirable *e.g.* in patients on NSAID therapy, in patients with Non Ulcer Dyspepsia, in patients with symptomatic gastro-esophageal reflux disease, and in patients with gastrinomas. The  
15 compound of the invention may also be used in patients in intensive care situations, in patients with acute upper gastrointestinal bleeding, pre- and postoperatively to prevent aspiration of gastric acid and to treat stress ulceration. Further, the compound of the invention may be useful in the treatment of psoriasis as well as in the treatment of *Helicobacter* infections and diseases related to these. The compound of the invention may  
20 also be used for treatment of inflammatory conditions in mammals, including man.

Any suitable route of administration may be employed for providing the patient with an effective dosage of omeprazole sodium form B according to the invention. For example, peroral or parenteral formulations and the like may be employed. Dosage forms include  
25 capsules, tablets, dispersions, solutions, suspensions and the like. Omeprazole sodium form B is, because of it being highly soluble in water, especially suitable for parenteral formulations, such as for intravenous administration.

According to the invention there is further provided a pharmaceutical composition  
30 comprising omeprazole sodium form B, as active ingredient, in association with a



pharmaceutically acceptable carrier, diluent or excipient and optionally other therapeutic ingredients. Compositions comprising other therapeutic ingredients are especially of interest in the treatment of *Helicobacter* infections. The invention also provides the use of omeprazole sodium form B in the manufacture of a medicament for use in the treatment of a gastric-acid related condition and a method of treating a gastric-acid related condition which method comprises administering to a subject suffering from said condition a therapeutically effective amount of omeprazole sodium form B.

The compositions of the invention include compositions suitable for peroral or parenteral administration. The compositions may be conveniently presented in unit dosage forms, and prepared by any methods known in the art of pharmacy.

Combination therapies comprising omeprazole sodium form B and other active ingredients in separate dosage forms may also be used. Examples of such active ingredients include anti-bacterial compounds, non-steroidal anti-inflammatory agents, antacid agents, alginates and prokinetic agents.

In the practice of the invention, the most suitable route of administration as well as the magnitude of a therapeutic dose of omeprazole sodium form B in any given case will depend on the nature and severity of the disease to be treated. The dose, and dose frequency, may also vary according to the age, body weight, and response of the individual patient. Special requirements may be needed for patients having Zollinger-Ellison syndrome, such as a need for higher doses than the average patient. Children and patients with liver diseases as well as patients under long term treatment will generally benefit from doses that are somewhat lower than the average. Thus, in some conditions it may be necessary to use doses outside the ranges stated below. Such higher and lower doses are within the scope of the present invention.

In general, a suitable dose range for parental administration is from 10 mg to 300 mg, and preferably from 20 mg to 80 mg.

A suitable oral dosage form may cover a dose range from 5 mg to 300 mg total daily dose, administered in one single dose or equally divided doses. A preferred dosage range is from 10 mg to 80 mg.

- 5 The compound of the invention may be combined as the active component in intimate admixture with a pharmaceutical carrier according to conventional techniques, such as the oral formulations described in WO 96/01623 and EP 247 983, the disclosures of which are hereby incorporated as a whole by reference.
- 10 The examples which follow will further illustrate the preparation of the compound of the invention, i.e. omeprazole sodium form B, but are not intended to limit the scope of the invention as defined hereinabove or as claimed below.

### Examples

15

#### Example 1

##### *Preparation of omeprazole sodium form B from omeprazole*

- 20 120 gram of omeprazole, 480 ml of isopropanol and 13.2 gram of NaOH(s) dissolved in 26.7 gram of water, was added to a 3-necked glass vessel. The slurry was stirred for an additional 40 minutes at ambient room temperature. The obtained solution was filtered through a clarifying filter and the filter was washed with 20 ml of isopropanol. The isopropanol wash was combined with the previous isopropanol solution containing the
- 25 product. The solution was seeded with 6 gram of omeprazole sodium form B in 25 ml of isopropanol. The slurry was stirred for an additional 25 hours and the product was filtered and dried at 40°C.

Yield 84.5 %.

Example 2*Preparation of omeprazole sodium form B from omeprazole sodium form A*

5 30 gram of omeprazole sodium form A, prepared according to example 3 below, and 25 ml of ethanol was added to a 3-necked glass vessel. The slurry was seeded with omeprazole sodium form B and then stirred for an additional 24 hours at room temperature. The product was then filtered and dried at 50°C.

Yield: 80%

10

Example 3*Preparation of omeprazole sodium form A from omeprazole*

15

14.8 kg sodium hydroxide was dissolved in 42 l water in a separate vessel.

120 kg omeprazole was added to 927 l isopropanol in a 4000 l glass lined reactor. The aqueous sodium hydroxide was charged to the slurry. Omeprazole was dissolved and the  
20 clear solution was filtered in a closed pressure filter to a 1200 l glass lined reactor. The solution was heated and 228 l methanol was charged at 50 °C to initiate the crystallization. The batch was seeded with a slurry of 1.2 kg omeprazole sodium methanol wet in isopropanol. The solution was cooled from 51 °C to - 8 °C. The formed slurry was kept at - 8 to - 9 °C for 4 hours with moderate stirring. Centrifuged substance was flushed with a  
25 cool mixture of isopropanol and methanol, 76 l and 20 l respectively, and then dried in a rotary dryer at approximately 35 mbar with a jacket temperature of 65 °C. Dried substance was de-lumped in a mill.

Yield: 126.0 kg omeprazole sodium methanol wet.

30

A sample of the omeprazole sodium methanol wet (32.3 kg) was charged into a rotary dryer. An equilibration process with steam in order to remove methanol was performed at 39 - 87 mbar and with a jacket temperature of 50 °C. The equilibration process took 3 days. Equilibrated substance was de-lumped in a mill.

5 Yield: 25.7 kg

#### Example 4

*Characterization of omeprazole sodium form B and omeprazole sodium form A using*  
10 *X-ray powder diffraction (XRPD)*

X-ray powder diffraction analysis was performed according to standard methods which can be found in e.g. Bunn, C. W. (1948), Chemical Crystallography, Clarendon Press, London; or Klug, H.P. & Alexander, L. E. (1974), X-Ray Diffraction Procedures, John Wiley and  
15 Sons, New York. The unit cell parameters for form A and B have been calculated from the X-ray powder diffractograms using the program "TREOR" by Werner, P.-E., Eriksson, L. And Westdahl, M., J. Appl. Crystallogr. 18 (1985) 367 - 370. The fact that the positions of all peaks in the diffractograms for form A and form B may be calculated using the respective unit cell parameters, proves that the unit cells are correct and that the  
20 diffractograms are indicative of the pure forms. The diffractogram of omeprazole sodium form B, prepared according to Example 1 in the present application, is shown in Figure 1 and the diffractogram of omeprazole sodium form A, prepared according to Example 3, is shown in Figure 2.

25 The peaks, identified with d-values calculated from the Bragg formula and intensities, have been extracted from the diffractograms for form A, form B and from the diffractogram obtained from material produced according to prior art, and are given in Table 1. In this table the unit cell parameters for forms A and B are also given. The relative intensities are less reliable and instead of numerical values the following definitions are used;

% Relative Intensity	Definition
25-100	vs (very strong)
10-25	s (strong)
3-10	m (medium)
5 1-3	w (weak)
<1	vw (very weak)

Some additional very weak peaks found in the diffractograms have been omitted from table 1.

10

#### Reference Example A

*Preparation of omeprazole sodium according to prior art in accordance with the method described in Example 2 in EP 124 495*

15

Omeprazole (1300 g; 3.77 mol) was added under vigorous mechanical stirring to a mixture of tetrahydrofurane (13 L) and 50% aqueous NaOH (296 g, 3.7 mol) and stirring was continued for 45 min. Trichloroethylene (5.7 L) was added and stirring was continued over night at room temperature. The mixture was cooled to +5°C and then stirred for 3 h. The precipitate was filtered off and the filter cake was washed with trichloroethylene (5 L) and dried under reduced pressure at 50°C giving omeprazole sodium salt (1314 g, 95%), m.p. 208-210 °C.

The product was analyzed using X-ray powder diffraction and gave the diffractogram depicted in Figure 3 and given above in Table 1. Some additional very weak peaks found in the diffractograms have been omitted from Table 1.

25

Table 1. X-ray powder diffraction data for omeprazole sodium form A, form B and according to prior art. Only peaks below  $2\theta = 40^\circ$  have been included.

All peaks noted for form A and form B can be indexed with the unit cells given below.

s Unit cell form A:  $a = 15.757 (3) \text{ \AA}$       Unit cell form B:  $a = 15.086 (6) \text{ \AA}$   
 $b = 8.126 (1) \text{ \AA}$                                        $b = 12.835 (4) \text{ \AA}$   
 $c = 15.671 (6) \text{ \AA}$                                        $c = 9.815 (3) \text{ \AA}$   
 $\beta = 94.21 (2)^\circ$                                        $\beta = 94.41 (3)^\circ$

Omeprazole sodium form A		Omeprazole sodium form B		Omeprazole sodium according to prior art	
d-value/ $\text{\AA}$	Relative intensity	d-value/ $\text{\AA}$	relative intensity	d-value/ $\text{\AA}$	Relative intensity
				17.8	vw
15.6	vs	9.8	vs	15.5	vs
				13.9	vw
				10.2	vw
				8.9	m
7.9	m	7.8	vw	8.0	m
7.2	m	6.7	s	7.2	m
				6.9	w
6.8	w	6.5	s	6.8	w
6.6	vw	6.2	vw		
6.5	w	5.90	m	6.5	vw
				6.4	vw
				6.2	vw
				5.91	vw
				5.83	w
				5.52	vw

Table 1, continued

Omeprazole sodium form A		Omeprazole sodium form B		Omeprazole sodium according to prior art	
d-value/Å	Relative intensity	d-value/Å	relative intensity	d-value/Å	Relative intensity
5.35	vw	5.76	vw	5.37	w
5.20	s	5.36	w	5.21	w
				5.15	m
				4.81	vw
4.70	vw	5.12	w	4.70	vw
				4.63	vw
4.40	vw	4.57	m	4.40	vw
4.29	vw	4.46	m		
				4.27	vw
4.17	vw	4.29	s	4.17	vw
3.935	s	4.11	m	3.938	w
				3.846	vw
3.831	w	3.963	m		
3.744	w	3.920	m	3.748	vw
				3.711	vw
3.611	w	3.713	s	3.610	vw
3.543	w	3.601	w	3.545	w
3.522	w	3.431	vw	3.519	vw
3.488	w	3.375	w		
				3.464	vw
3.411	vw	3.254	vw	3.410	vw
				3.304	vw
				3.256	vw
				3.151	vw

Table 1, continued

Omeprazole sodium form A		Omeprazole sodium form B		Omeprazole sodium according to prior art	
d-value/Å	Relative intensity	d-value/Å	relative intensity	d-value/Å	Relative intensity
3.125	m	3.173	vw	3.125	vw
				3.079	vw
3.021	vw	3.137	w	3.026	vw
2.919	w	3.119	m	2.911	vw
				2.854	vw
2.833	w	3.050	w		
				2.775	vw
2.676	vw	2.993	w		
2.626	vw	2.980	m		
2.606	vw	2.906	m	2.601	vw
				2.553	vw
2.534	vw	2.892	m		
2.425	vw	2.793	vw	2.430	vw
		2.624	vw		
		2.589	vw		
		2.499	vw		
		2.447	vw		
		2.402	vw		
		2.372	vw		
		2.283	vw		



## CLAIMS

1. Omeprazole sodium form B, characterized in being thermodynamically stable.
- 5 2. Omeprazole sodium form B, characterized in being essentially non-hygroscopic.
3. Omeprazole sodium form B according to claim 1 or claim 2, characterized in providing an X-ray powder diffraction pattern exhibiting substantially the following d-values and intensities;

d-value/Å	relative intensity	d-value/Å	relative intensity
9.8	vs	3.37	w
7.8	vw	3.25	vw
6.7	s	3.17	vw
6.5	s	3.14	w
6.2	vw	3.12	m
5.9	m	3.05	w
5.8	vw	2.99	w
5.4	w	2.98	m
5.1	w	2.91	m
4.6	m	2.89	m
4.5	m	2.79	vw
4.3	s	2.62	vw
4.1	m	2.59	vw
3.96	m	2.50	vw
3.92	m	2.45	vw
3.71	s	2.40	vw
3.60	w	2.37	vw
3.43	vw	2.28	vw

4. Omeprazole sodium form B according to any of claims 1-3, characterized by having a monoclinic unit cell with parameters

$$a = 15.09 \text{ \AA}, b = 12.83 \text{ \AA}, c = 9.82 \text{ \AA}, \beta = 94.4^\circ.$$

5 5. A process for the preparation of omeprazole sodium form B as defined in any of claims 1-4, which includes the step of;

- a) preparing the sodium salt of omeprazole by addition of an aqueous base to omeprazole in a solvent mixture comprising an alcohol and water,
- b) allowing the solution to crystallize, optionally using omeprazole sodium form B to  
10 induce crystallization;, and
- c) isolating the omeprazole sodium form B thus obtained.

6. A process according to claim 5, wherein said aqueous base used in step a) is sodium hydroxide.

15

7. A process according to any of claims 5-6, wherein said alcohol used in step a) is isopropanol.

8. A process for the preparation of omeprazole sodium form B as defined in any of claims  
20 1-4, comprising the steps of;

- a) dissolving omeprazole sodium of any form, or a mixture of any forms, in a solvent mixture comprising alcohol and water;
- b) allowing the solution to crystallize, optionally using omeprazole sodium form B to induce crystallization, and
- 25 c) isolating the omeprazole sodium form B thus obtained.

9. A pharmaceutical formulation comprising omeprazole sodium form B as defined in any of claims 1-4 in admixture with a pharmaceutically acceptable excipient.


10. A pharmaceutical formulation suitable for i.v. administration comprising omeprazole sodium form B as defined in any of claims 1-4 in admixture with a pharmaceutically acceptable excipient.

5 11. The use of omeprazole sodium form B as defined in any of claims 1-4, as active ingredient in the manufacture of medicament for use in treatment of gastrointestinal disorders.


12. The use of omeprazole sodium form B as defined in any of claims 1-4 in the  
10 manufacture of a pharmaceutical formulation for i.v. administration.

13 A method of treatment of gastrointestinal disorders which comprises administration of a therapeutically effective amount of omeprazole sodium form B as defined in any of claims 1-4, to a patient suffering from gastrointestinal disorders.


1 / 3



2 / 3



3 / 3



1  
INTERNATIONAL SEARCH REPORT

International application No.

PCT/SE 98/01124

## A. CLASSIFICATION OF SUBJECT MATTER

IPC6: C07D 401/12, A61K 31/44

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC6: C07D

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

SE,DK,FI,NO classes as above

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

CAS-ONLINE

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	EP 0124495 A2 (AKTIEBOLAGET HÄSSLE), 7 November 1984 (07.11.84)  -- -----	1-12

☐ Further documents are listed in the continuation of Box C. ☒ See patent family annex.

- \* Special categories of cited documents
- "A" document defining the general state of the art which is not considered to be of particular relevance
- "E" earlier document but published on or after the international filing date
- "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- "O" document referring to an oral disclosure, use, exhibition or other means
- "P" document published prior to the international filing date but later than the priority date claimed
- "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- "X" document of particular relevance: the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- "Y" document of particular relevance: the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
- "&" document member of the same patent family

Date of the actual completion of the international search

23 Sept 1998

Date of mailing of the international search report

12-10-1998

Name and mailing address of the ISA:

Swedish Patent Office  
Box 5055, S-102 42 STOCKHOLM  
Facsimile No. +46 8 666 02 86

Authorized officer

Göran Karlsson  
Telephone No. +46 8 782 25 00

## INTERNATIONAL SEARCH REPORT

International application No.

PCT/SE 98/01124

## Box I Observations where certain claims were found unsearchable (Continuation of Item 1 of first sheet)

This international search report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.: 13  
because they relate to subject matter not required to be searched by this Authority, namely:  
A method for treatment of the human or animal body by therapy,  
see rule 39.1.
2. ☐ Claims Nos.:  
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:
3. ☐ Claims Nos.:  
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

## Box II Observations where unity of invention is lacking (Continuation of Item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.  
☐ No protest accompanied the payment of additional search fees.



**INTERNATIONAL SEARCH REPORT**  
Information on patent family members

27/07/98

International application No.

PCT/SE 98/01124

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
EP 0124495 A2	07/11/84	SE 0124495 T3	
		AU 563842 B	23/07/87
		AU 2525784 A	06/09/84
		BG 44538 A	15/12/88
		BG 60837 B	30/04/96
		CA 1264751 A	23/01/90
		CS 241150 B	13/03/86
		CS 8401515 A	13/06/85
		DK 99584 A	05/09/84
		DK 160044 B,C	21/01/91
		FI 83649 B	30/04/91
		FI 840851 A	05/09/84
		GB 2137616 A,B	10/10/84
		HK 13590 A	02/03/90
		HR 930428 B	30/04/96
		JP 1651336 C	30/03/92
		JP 3013233 B	22/02/91
		JP 59167587 A	21/09/84
		LT 2253 A	15/11/93
		LT 94793 R	15/11/93
		PT 78191 B	05/08/86
		SE 8301182 D	00/00/00
		SI 8410397 A	31/10/95
		SU 1314953 A	30/05/87
		US 4738974 A	19/04/88